Olatorepatide  (Synonyms: Olatorepatidum)

Olatorepatide (Olatorepatidum) is a dual gastric inhibitory polypeptide (GIP) receptor and glucagon like peptide 1 (GLP-1) receptor agonist, with antidiabetic effect^[1].

5020.63

C₂₃₅H₃₅₇N₄₉O₇₂

2675496-01-0

Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Tyr-Leu-Glu-Lys-Ile-Ala-Ala-Gln-Glu-Phe-Val-Asn-Trp-Leu-Leu-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-{Lys((AEEA)2-γGlu-C20 diacid)}-NH2

Y-{Aib}-EGTFTSDYSIYLEKIAAQEFVNWLLAGGPSSGAPPPS-{Lys((AEEA)2-γGlu-C20 diacid)}-NH2

O=C([C@@H](N)CC1=CC=C(O)C=C1)NC(C)(C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(NCC(N2[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N3[C@H](C(N4[C@H](C(N5[C@H](C(N[C@H](C(N[C@H](C(N)=O)CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@H](NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)=O)=O)=O)=O)CO)=O)CCC5)=O)CCC4)=O)CCC3)=O)C)=O)=O)CO)=O)CO)=O)CCC2)=O)=O)=O)C)=O)CC(C)C)=O)CC(C)C)=O)CC6=CNC7=CC=CC=C67)=O)CC(N)=O)=O)C(C)C)=O)CC8=CC=CC=C8)=O)CCC(O)=O)=O)CCC(N)=O)=O)C)=O)C)=O)[C@H](CC)C)=O)CCCCN)=O)CCC(O)=O)=O)CC(C)C)=O)CC9=CC=C(O)C=C9)=O)[C@H](CC)C)=O)CO)=O)CC%10=CC=C(O)C=C%10)=O)CC(O)=O)=O)CO)=O)[C@@H](C)O)=O)CC%11=CC=CC=C%11)=O)[C@@H](C)O)=O)=O)CCC(O)=O)=O)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Olatorepatidum (Olatorepatide). WHO Drug Information, Vol. 37, No. 4, 2023.